Entity
  • Intelligencia AI

    Created in 2017


  • Up & running (A)
    Existing signals show a regular activity
  • Social networks

    12,061
  • Activities

  • Technologies

  • Entity types

  • Location

    180 Varick St 6th floor, New York, NY 10014, USA

    New York

    United States of America

  • Employees

    Scale: 51-200

    Estimated: 134

  • Engaged catalyst

    0
    0 0
  • Added in Motherbase

    3 months, 3 weeks ago
Description
  • Value proposition

    Applying machine learning in drug development

    Intelligencia AI uses artificial intelligence to de-risk drug development. Our platform focuses on estimating the risk of clinical trials, and interpreting the multitude of factors that contribute to that risk. We bridge the gap between innovation and risk reduction, with the ultimate goal of bringing novel therapies to patients faster.

    Our interdisciplinary team of software engineers, AI practitioners, scientists, and drug developers combines and interprets disparate data across the life sciences industry. Our platform offers a suite of functionalities that provide unprecedented data clarity and Machine-Learning predictions to enable critical decision-making.

    We currently work with several of the largest global pharmaceutical companies as well as mid-size and smaller biotechnology companies.

    Diseases will impact nearly every individual. At Intelligencia AI, we work to make a difference.

    Artificial Intelligence, Data Science, Machine Learning, Data Visualization, Experience Design, Healthcare, Pharmaceuticals, Biotechnology, Drug Development, and Clinical Trials

  • Leading AI Drug Development Company | Intelligencia AI

    Revolutionize drug development with AI-driven insights. Enhance portfolio strategy, reduce risks, and make informed decisions. Our solutions predict success.

  • https://www.intelligencia.ai/
Catalyst interactions
Catalyst TypeTweets Articles
No interactions
Social network dynamics
Similar entities
BETA
Loading...
Loading...